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Abstract
Aims/hypothesis Gastrin has been implicated in islet
growth/neogenesis, and proton pump inhibitors (PPIs) have
been shown to increase endogenous gastrin levels in
animals and humans. Therefore, we investigated the effect
of PPIs in a model of type 2 diabetes, Psammomys obesus.
Methods P. obesus (morning blood glucose [mBG] 16.9±
0.6 mmol/l) were treated with vehicle or different doses (1–
15 mg/kg) of lansoprazole for 17 days.
Results Treatment with lansoprazole resulted in up to
ninefold dose-dependent increases in endogenous gastrin
levels (p<0.05 for 10 mg/kg lansoprazole vs vehicle).
There was a significant reduction in mBG levels in all
animals in the high-dose lansoprazole groups during the
17 day treatment period, whereas there was no significant
improvement in mBG in animals in the vehicle groups. The
mBG at end of study was 18.2±2.1, 8.7±2.2 (p<0.01), and
6.1±2.3 (p<0.001) mmol/l for vehicle and lansoprazole 10
and 15 mg/kg, respectively. The animals treated with
15 mg/kg lansoprazole, compared with vehicle, had a 2.3-
fold increase in the intensity of insulin staining in beta cells
(p=0.0002) and 50% higher beta cell mass (p=0.04).
Conclusions/interpretations The PPI lansoprazole had sig-
nificant glucose-lowering effects in an animal model of
type 2 diabetes, an effect that is most likely mediated
through an increase in endogenous gastrin levels.
Keywords Animal model.Beta cell mass.Gastrin.
Glycaemic control.Proton pump inhibitor.
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Abbreviations
BCM Beta cell mass
BW Body weight
mBG Morning blood glucose
PPI Proton pump inhibitor
SPA Scintillation proximity assay
Introduction
The consistent finding of reduced functional pancreatic beta
cell mass (BCM) not only in type 1 diabetes but also in type 2
diabetes has increased the focus on finding new treatments
that may increase and/or cause regeneration of functional
BCM. Gastrin has been shown to increase proliferation of
human and rodent duct-like pancreatic cells in culture, and
administration of gastrin stimulates beta cell neogenesis and
expansion of the BCM in rodents [1, 2]. During treatment
with proton pump inhibitors (PPIs), endogenous gastrin
levels are increased in humans and rodents, and in a recent
publication Suarez-Pinzon et al. showed that PPI treatment
of mice in a model of type 1 diabetes resulted in an almost
threefold increase in endogenous gastrin levels and improve-
ment in glycaemia [3].
Since no data have been published on the effect of
gastrin or PPIs in type 2 diabetes, we decided to investigate
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beneficial effects on glycaemic control in a type 2 diabetes
animal model, the gerbil Psammomys obesus. When this
gerbil is fed a high-energy diet, morning blood glucose
(mBG) levels are distinctly increased, with subsequent/
concomitant loss of beta cell function and mass [4].
Methods
Animals Male and female P. obesus (Harlan, Jerusalem,
Israel) were fed low-energy (10 kJ/g) chow until the age of
14–15 weeks, after which they were transferred to an ad
libitum high-energy (13 kJ/g) diet during which body
weight (BW), mBG and HbA1c were monitored for 4
weeks. The animals that showed increased mBG levels,
defined as mBG >10 mmol/l on two consecutive readings,
were used in the treatment study.
P. obesus were treated with vehicle (n=5) or 1 mg/kg
(n=8), 3 mg/kg (n=11) or 10 mg/kg (n=7) lansoprazole in
the first study. At the start of the experiment there were 10–
12 animals in each group, except for the 10 mg/kg group,
which was smaller due to lack of compound. During the
study, five animals in the vehicle group and two in the
1 mg/kg group had to be killed due to severely elevated
mBG and ketoacidosis. Two animals, one from the 3 mg/kg
group and one from the 10 mg/kg group, died due to dosing
into the lungs. They were removed from all the analyses.
The second study consisted of animals dosed with vehicle
(n=8) or 10 mg/kg (n=8) or 15 mg/kg (n=8) lansoprazole.
Both studies were conducted over 2.5 weeks, during which
mBG, BW and HbA1c were monitored, and gastrin levels
were measured at the end of the study. Pancreases from the
groups receiving 10 and 15 mg/kg were evaluated histo-
logically for insulin content and BCM.
The study was approved by the Animal Experiments
Inspectorate, Ministry of Justice, Denmark.
Formulation of lansoprazole Lansoprazole (L8533; Sigma-
Aldrich, Broendby, Denmark) was suspended in vehicle
(0.6% carboxymethylcellulose, 0.2% NaHCO3) to the final
dose volume of 2 ml/kg.
mBG and HbA1c Bloodsampleswerecollected fromthetail,
and mBG and HbA1c measured as previously described [5].
Endogenous gastrin Gastrin levels were measured in
samples collected from the aorta using a competition
scintillation proximity assay (SPA). Briefly, SPA beads,
coated with anti-rabbit antibody, were incubated with rabbit
anti-gastrinantibodyand
125I-labelled Tyr12-gastrin (human).
Sample, standard or control was added to the plates,
followed by 10 μl of antibody rabbit-anti-gastrin serum
(#2609 11/10-73; gift from J. Rehfeld, University Hospital,
Copenhagen, Denmark) diluted in assay buffer, 10 μlt r a c e r
([
125I-Tyr
12]-gastrin I [human]), 0.37 MBq/ml NEX176
(Amersham, Cardiff, UK) and 10 μl bead solution (Anti-
Rabbit Coupled Polystyrene SPA RPQ0742; GE Healthcare,
Umeå, Sweden). The plates were mixed and left for 6–
24 h, after which they were centrifuged and counted
(LEADseeker; GE Healthcare).
Pancreas histology The pancreases were examined histo-
logically, as previously described [5]. Briefly, pancreases
were fixed in paraformaldehyde and sectioned according
to the smooth fractionator principle with F=1/4 of the
f r a g m e n t si ne a c ho ft h et w oc a p s u l e s[ 6]. The sections
w e r es t a i n e df o ri n s u l i nt ov i s u a l i s eb e t ac e l l s .B C Mw a s
evaluated stereologically in two to three sections with the
observer blinded to the origin of the sections. The insulin
staining intensity was graded semiquantitatively on a scale
of 0–5, with 0 being equal to islets characterised by
absence of insulin staining while 5 equals islets with
insulin staining as seen in normal rat pancreas. The
grading was carried out with the observer blinded to the
origin of the sections.
Statistical analysis Data were analysed using non-
parametric (Kruskal–Wallis) ANOVA with Dunn’s multiple
comparisons as post test or a non-parametric paired t test
(Wilcoxon). p≤0.05 was considered significant. Data are
presented as mean±SEM.
Results
Glycaemic control In the first experimental setup, 2.5 weeks
of treatment had no significant effects on mBG in the
vehicle and low-dose lansoprazole (1 and 3 mg/kg) groups.
mBG at end of study was 18.2±2.1, 21.7±1.5 and 14.4±
2.2 mmol/l for vehicle (n=5) and lansoprazole 1 mg/kg
(n= 8 )a n d3m g / k g( n=11), respectively (Fig. 1a). The
animals treated with the highest dose (10 mg/kg) had
significantly lower mBG (8.7±2.2 mmol/l, p<0.01) at the
end of the study. At start of treatment, there were no
significant differences in mBG and HbA1c for the different
treatment groups (Fig. 1a, b). At the end of the study
period, HbA1c levels in the animals treated with the highest
dose (10 mg/kg) of lansoprazole were significantly lower
(7.7±0.6%) than with vehicle (10.3±0.5%, p<0.05) or
with 1 mg/kg (11.0±0.5, p<0.05) or 3 mg/kg lansoprazole
(9.5±0.5%, p<0.05; Fig. 1b).
In a subsequent study, primarily focusing on pancreas
histology and a higher dose of lansoprazole, similar results
were obtained (Fig. 1c, d). There was no reduction in mBG
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was 13.6±1.5 mmol/l. In the lansoprazole 10 mg/kg group
mBG was significantly reduced to 5.0±1.4 (p<0.001) and
in the 15 mg/kg group to 6.1±2.3 mmol/l (p<0.001
compared with vehicle) (Fig. 1c). Likewise, HbA1c in the
animals treated with 10 and 15 mg/kg of lansoprazole was
significantly lower (6.9±0.3% and 7.0±0.3% respectively,
p<0.01) than in the vehicle-treated animals (10.4±0.7%;
Fig. 1d).
BW During the study, no difference was observed in BW
gain between the groups (data not shown).
Endogenous gastrin After 17 days of treatment with
lansoprazole (1, 3 and 10 mg/kg), endogenous gastrin levels
were dose-dependently increased by up to ninefold in the
animals treated with 10 mg/kg (p<0.05 vs vehicle, Fig. 2a);
no further increase was seen in the 15 mg/kg group (Fig. 2b).
BCM and intensity of insulin staining Stereological quan-
tification of BCM revealed that the animals treated with 10
and 15 mg/kg lansoprazole had 40% (NS) and 50% (p=
0.04) higher BCM, respectively, compared with vehicle-
treated animals (Fig. 2c).
Immunohistochemical analysis of the pancreas showed a
2.3-fold increase in the intensity of the insulin staining in
the lansoprazole-treated animals compared with the vehicle-
treated animals (p=0.0002; Fig. 2d).
Discussion
Our results show that the PPI lansoprazole increases
endogenous gastrin levels in P. obesus, glycaemic control
Fig. 2 Plasma gastrin levels (a, b), beta cell mass (c) and intensity of
insulin staining in pancreatic sections (d) from Psammomys obesus after
17 days of treatment with vehicle or different doses of lansoprazole.
a White bar, vehicle (n=5); very pale grey bar, lansoprazole 1 mg/kg
(n=8); pale grey bar, lansoprazole 3 mg/kg (n= 1 1 ) ;d a r kg r e yb a r ,
lansoprazole 10 mg/kg (n=7).b White bar, vehicle (n=5); dark grey bar,
lansoprazole 10 mg/kg (n=7); black bar, lansoprazole 15 mg/kg (n=8).
c, d White bar, vehicle (n=5); dark grey bar, lansoprazole 10 mg/kg (n=
7); black bar, lansoprazole 15 mg/kg (n=8). Data are expressed as
mean±SEM. *p<0.05 vs vehicle-treated animals; **p<0.01 vs vehicle-
treated animals
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Fig. 1 Morning blood glucose
(BG) (a, c) and HbA1c (b, d)i n
Psammomys obesus before and
during treatment with vehicle or
different doses of lansoprazole.
a, b Black squares, vehicle
(n=5); white squares, lansopra-
zole 1 mg/kg (n=8); black
circles, lansoprazole 3 mg/kg
(n=11); white circles,
lansoprazole 10 mg/kg (n=7).
c, d Black squares, vehicle
(n=8); white squares, lansopra-
zole 10 mg/kg (n=8); black
circles, lansoprazole 15 mg/kg
(n=8). HE, high energy. Data
are expressed as mean±SEM
2222 Diabetologia (2010) 53:2220–2223is almost normalised and BCM and insulin content of the
pancreas are increased. Several studies have shown that
PPIs elevate gastrin levels in both rodents and humans, and
in this study we show this also to be the case in P. obesus.I t
has been shown that treatment with gastrin alone can
induce formation of new beta cells under different
conditions [1, 2]; however, from the present study we
cannot determine whether the increased beta cell mass is
due to an increase in neogenesis and/or proliferation or a
decrease in apoptosis. Further studies that directly address
these mechanisms are warranted also in light of the
possibility that rodents have a higher capacity for regener-
ation of BCM than humans.
Although we did not directly measure beta cell function,
there was a significant reduction in mBG and HbA1c, which
are both clinically relevant variables to measure for any
agent that influences beta cell function or BCM.
Even though it is known that PPIs stimulate gastrin
production, treatment with PPIs will result in very different
pharmacokinetic profiles as compared with gastrin injec-
tions. Therefore, it could not be expected that PPIs would
have the same effect on expansion of beta cell mass and
function as has previously been demonstrated with gastrin.
Whereas gastrin, in the doses used in the in vivo rodent
studies, has a short half-life in rodents (less than 10 min;
T. B. Bödvarsdóttir, L. Pridal, unpublished results), which
results in a high exposure for a short time period, PPI
treatment, in contrast, will result in a chronic elevation of
gastrin levels to a few times above normal. A direct
comparison of gastrin and PPIs is needed in order to clarify
whether PPI treatment is superior to gastrin or vice versa.
But, since PPIs are readily available as oral agents with a
long-standing record of safety, the data presented here from
lansoprazole-treated P. obesus warrant further studies of the
clinical benefits of PPIs in type 2 diabetes.
In conclusion, the PPI lansoprazole has significant
glucose-lowering effects in an animal model of type 2
diabetes, and thus PPIs might have the potential to become
a new class of safe glucose-lowering agents, provided these
findings can be extrapolated to other PPIs and humans.
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